Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Friedrich Bayer

Johann Friedrich Weskott

Bayer Aktiengesellschaft

The Andersons, Inc., an agriculture company, operates in trade, renewables, and plant nutrient sectors in the United States and internationally. The company's Trade segment operates grain elevators; stores commodities; and provides grain marketing, risk management, and origination services to its customers and affiliated ethanol facilities. This segment also engages in the commodity merchandising business, as well as offers logistics for physical commodities, such as whole grains, grain products, feed ingredients, domestic fuel products, and other agricultural commodities. Its Renewables segment produces, purchases, and sells ethanol, and co-products, as well as offers facility operations, risk management, and ethanol and coproducts marketing services to the ethanol plants it invests in and operates. The company's Plant Nutrient segment manufactures, distributes, and retails agricultural and related plant nutrients, corncob-based products, and pelleted lime and gypsum products; and crop nutrients, crop protection chemicals, and seed products, as well as provides application and agronomic services to commercial and family farmers. It also offers warehousing, packaging, and manufacturing services to nutrient producers and other distributors; and manufactures and distributes various industrial products, such as nitrogen reagents for air pollution control systems that are used in coal-fired power plants, and water treatment and dust abatement products. In addition, this segment produces corncob-based products for laboratory animal bedding and private-label cat litter, as well as absorbents, blast cleaners, carriers, and polishers; professional lawn care products for golf course and turf care markets; fertilizer and weed and pest control products; pelleted lime, gypsum, and value add soil amendments; and specialty ag liquids, seed starters, zinc, and industrial liquids. The Andersons, Inc. was founded in 1947 and is based in Maumee, Ohio.

The Andersons, Inc.

Angelini Pharma is an international pharmaceutical company focused on the research, development, and commercialization of health solutions with a preeminent focus on brain health, including mental health and epilepsy, and consumer healthcare.

Angelini Pharma

Bunge Limited operates as an agribusiness and food company worldwide. It operates through four segments: Agribusiness, Refined and Specialty Oils, Milling, and Sugar and Bioenergy. The Agribusiness segment purchases, stores, transports, processes, and sells agricultural commodities and commodity products, including oilseeds primarily soybeans, rapeseed, canola, and sunflower seeds, as well as grains primarily wheat and corn; and processes oilseeds into vegetable oils and protein meals. This segment offers its products for animal feed manufacturers, livestock producers, wheat and corn millers, and other oilseed processors, as well as third-party edible oil processing and biofuel companies; and for industrial and biodiesel production applications. The Refined and Specialty Oils segment sells packaged and bulk oils and fats that include cooking oils, shortenings, margarines, mayonnaise, and other products for baked goods companies, snack food producers, confectioners, restaurant chains, foodservice operators, infant nutrition companies, and other food manufacturers, as well as grocery chains, wholesalers, distributors, and other retailers. The Milling segment provides wheat flours and bakery mixes; corn milling products that comprise dry-milled corn meals and flours, wet-milled masa and flours, and flaking and brewer's grits, as well as soy-fortified corn meal, corn-soy blends, and other products; whole grain and fiber ingredients; quinoas and millets; die-cut pellets; and non-GMO products. The Sugar and Bioenergy segment produces sugar and ethanol; and generates electricity from burning sugarcane bagasse. Bunge Limited was founded in 1818 and is headquartered in St. Louis, Missouri.

Johann P. G. Bunge

Bunge Limited

Bayer | Pharmaceuticals

Bayer | Crop Science

Climate

Bayer Crop Science | Innovation Ecosystem

Bayer | Ophthalmology

Bayer | Consumer Health

Bayer Foundation

Bayer | Cardiopulmonary

Bayer | Oncology

Bayer | Business Consulting

Digital Hub Warsaw I Bayer

Bayer Co.Lab

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to serve the most essential human needs of health and nutrition. At the same time, we strive to address some of the world’s biggest challenges presented by a growing and aging global population.
At Bayer, we’re committed to driving sustainable development and generate a positive impact with our businesses.
Through the power of science, we’re pioneering new possibilities that advance life for all of us. That means reimagining how we care for ourselves and one another by empowering everyday health, improving approaches to patient care, and finding better ways to nourish our communities around the world.

Data Privacy Statement & Imprint: https://www.bayer.com/en/glob-li-bayer-en-dps-imprint.aspx

BlueRock Therapeutics

Covercress

Bill & Melinda Gates Foundation

Temasek Holdings

Bayer

Parkinson’s disease gradually takes away a person’s ability to do what they love. We’re taking a new approach to treatment with two potentially regenerative therapies, both in various stages of clinical trials. 
 
Rather than replacing dopamine lost to Parkinson’s disease like current drugs do, cell therapy seeks to physically replace the cells that produce it. Gene therapy, on the other hand, would target existing neurons, aiming to help the brain heal itself.


#Parkinson #InnovationInHealthcare

Bayer is deeply honored to have forged a partnership with the Emirates Society of Ophthalmology, dedicated to advancing eye care solutions for patients throughout the #UAE. 
 
Hugo Hagen, Senior Bayer Representative and Country Division Head of Pharmaceutical at Bayer Middle East, along with Sheikha Dr. Noura Al Qassimi, President of the Emirates Society of Ophthalmology, came together to formalize a five-year partnership through the signing of a Memorandum of Understanding (MoU), to establish RAFEK. 

RAFEK is the first of its kind national patient centric project, aiming to address gaps in the patient journey in the field of ophthalmology, to enhance treatment outcomes using data analytics, which perfectly resonate with Bayer's overarching mission of "Health for All, Hunger for None". 

#TeamBayer #BayerMiddleEast #BayerME #HealthForAll #eso

We’re delighted that so many strong, visionary women have already found their way to us. On today's International Day of Women and Girls in Science, we would like to share the thoughts of three of our employees Fahriba Raisa, Silvia Cerezo and Satish Kamath. 
Although they are very different in terms of age, professional experience and field of work, they share one essential approach: the importance of the role of women and girls in science.

"My Journey as a Woman in Science" 
➡ https://lnkd.in/eMex3ZMc

"Science & Gender Equality – Reflections of a Surprised Uncle" 
➡ https://lnkd.in/ecMRhidx

#BayerCareer #TeamBayer #BetterTogether #BeBayer #WomenInScience #GirlsInSTEM

#AI applications bring great potential to accelerate product development and improve the way products are manufactured and delivered to customers in agriculture. 

Find out how:

G4A Girişim Hızlandırma Programı’mızın yeni dönem başvuru detayları Harvard Business Review Türkiye Dergisi’nde!

Sağlık ve tarım alanıdaki girişimcilerin başvurularını 11 Şubat’a kadar g4a.bayer.com.tr web sitemiz üzerinden bekliyoruz!

#BayerTürkiye #G4A #Girişim

We're working at full speed to redesign our company. Listen to our CEO Bill Anderson talking about what this new system essentially means.

Bei #ChronicKidneyDisease sind nicht nur die Nieren betroffen - auch das Herz kann Schaden nehmen! ❤ Eine verminderte Nierenfunktion belastet das Herz und erhöht das Risiko einer Herzinsuffizienz.
 
Erfahre mehr über Chronische Nierenerkrankungen auf unserer Website www.niereleidetleise.at
 
#ThinkKidneyCare #CKD

Inspirados na qualidade de vida dos pacientes, nossos investimentos no combate ao câncer têm sido cada vez mais expressivos. 
 
Além de iniciativas como a criação do Centro de Pesquisa e Inovação em Boston-Cambridge em junho de 2022*, também temos nos dedicado ao desenvolvimento de novos medicamentos. 
 
Cuide da sua saúde, e conte com a Bayer para continuar fomentando saúde para todos, fome para ninguém. 
 
#SeÉBayerÉBom #InspiradosNoPaciente #InspiredByYou 
 
#PraTodosVerem: esse post tem texto alternativo. 
 
*Fonte (ing.): https://lnkd.in/dxSnMtRj

In the face of major global challenges such as global warming, the COVID-19 pandemic, or the looming food shortage, scientific innovation is absolutely indispensable. And to make the best use of the expertise, brilliant minds and ideas across organizations, research collaborations are essential to achieve the scientific discoveries the world so urgently needs.

However, some view scientific partnerships, particularly between the public and private sector, with a degree of skepticism. But without trust in the scientific process and the actors involved, the best innovations are developed on a shaky foundation. Often, this distrust is rooted in the fact that people do not know enough about what these collaborations look like. 

In order to strengthen trust in science, we at Bayer set up a public transparency register: The Bayer Science Collaboration Explorer lists information on our science collaborations with universities, public research institutions & individuals. Because we want to show everyone what we do and why we are doing it. After launching the Explorer in Germany and the US, this initiative for more #transparency will now also include Swiss-based collaborations.

We invite you to explore for yourself: bayer.com/bsce

Metric
Company Name	Bayer Aktiengesellschaft	The Andersons, Inc.	Angelini Pharma	Bunge Limited
Symbol	BAYN	ANDE		BG
MSH ID	COM:BAYER	COM:ANDERSONSINC	COM:ANGELINIPHARMA	COM:BUNGE
Market	STOCKS	STOCKS	PRIVATE	STOCKS
Sector	Healthcare	Consumer Defensive	Healthcare & Health Services	Consumer Defensive
Industry	Drug Manufacturers - General	Food Distribution	Pharmaceuticals	Agricultural Farm Products
Country	DE	US	IT	US
Stage
Employee Count	98.19K	2.26K		23K
Website	bayer.com	andersonsinc.com	angelinipharma.com	bunge.com
LinkedIn	bayer	theandersonsinc		bunge
Founders

Metric
Market Cap	27.44B	1.59B		15.74B
Enterprise Value
Monthly Web Traffic		9.42K	15.77K	129.39K
Web Traffic Growth		0.09	-0.39	-0.28
Valuation
Raised Capital

Metric
Revenue	50.32B	14.75B	59.53B
Revenue (LTM)
Revenue (NTM)
Gross Profit	29.46B	745.36M	3.91B
EBITDA	13.04B	378.21M	2.65B
Operating Income	8.88B	253.10M	2.20B
Net Income	-3.11B	101.19M	2.24B
EPS	-3.16	3	15.07
Diluted EPS	-3.16	2.94	14.88
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.59	0.06	0.08
Operating Profit Margin	0.08	0.02	0.05
EBITDA Margin	0.26	0.03	0.04
Net Profit Margin	-0.03	0.01	0.04
Return on Equity	-0.04	0.08	0.20
Return on Assets	-0.01	0.04	0.09
Return on Capital Employed	0.04	0.11	0.18

COM:BAYER

Bayer AG

Last Close

19.80

25/11 09:25

Market Cap

25.98B

Beta: -

Volume Today

648.33K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-7.66	64.17	6.79
P/B Ratio	0.84	1.19	1.20
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.63	0.14	0.28
EV Multiple	-0.89	5.42	5.10

Metric
Days Sales Outstanding		18.38	14.95
Days Payables Outstanding	118.44	19.34	25.52
Days Inventory Outstanding	257.77	30.41	57.49
Operating Cycle	389.93	49.28	75.07
Cash Conversion Cycle	270.05	43.40	50.97
Asset Turnover	0.39	4.17	2.35

Metric
Operating Cash Flow	4.29B	946.75M	3.29B
Free Cash Flow	1.38B	796.31M	2.16B
Cash Flow to Debt	0.16	1.75	2.66
Operating Cash Flow/Sales	0.16	0.08	0.06
Free Cash Flow Yield	-0.02	0.57	0.03

Metric
Cash & Equivalents	6.24B	643.85M	2.62B
Accounts Receivable	727.74M	468.97M	256M
Inventory	14.73B	1.17B	7.57B
Goodwill	34.12B	127.86M	489M
Debt to Capitalization	0.57	0.31	0.35
Debt to Assets	0.41	0.18	0.24
Current Ratio	1.13	1.80	2.02
Quick Ratio	0.87	1.44	1.10

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.00	0.00
R&D to Revenue	0.12
SG&A to Revenue	0.05	0.03